mRNA Technology for Next Generation Treatment
BioNTech is building 3 therapeutic platforms using mRNA technologies for pharmacologically optimized protein coding RNA for targeted in vivo delivery
- Cancer immunotherapies
- Infectious disease vaccines
- Protein replacement
BioNTech is part of the EAVI2020 consortium for the development of an effective HIV vaccine. BioNTech will develop novel, highly immunogenic, prophylactic and therapeutic vaccine candidates based on our A.I.R technology platform. For more information visit the EAVI2020 Website.